Zymeworks (ZYME) IPO Opens 4% Higher

Today's IPO for Zymeworks (NYSE: ZYME) opened for trading at $13.50 pricing of its initial public offering of 4,500,000 common shares at a price to the public of U.S.$13.00 per share.

In addition, Zymeworks has granted the underwriters a 30-day over-allotment option to purchase up to an additional 675,000 common shares at the initial public offeringprice, less underwriting discounts and commissions.

Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Canaccord Genuity Corp. is acting as lead manager. Cormark Securities Inc. is acting as co-manager. MTS Securities, LLC served as financial advisor to Zymeworks in the offering.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

You May Also Be Interested In

• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• Wolfe Research Starts SpaceX (SPCX) at Outperform
• How Musk's tactics left investors clamoring for SpaceX stock and ignoring risks